Biohaven outlicensed global rights to opakalim, a Kv7-targeting small molecule in pivotal epilepsy testing, to SK Biopharmaceuticals while receiving non-dilutive financing for its pipeline. The transaction expands SK Bio’s U.S. prospects and creates a new route toward commercialization for a drug that is positioned in late-stage development for epilepsy. For Biohaven, the deal is designed to preserve cash while keeping opakalim progressing under a partner’s commercialization plan. For the biotech sector, the key signal is that late-stage epilepsy assets continue to attract strategic licensing deals, especially when partnered rights and geography can be structured to match each company’s strengths. Both parties will now focus on regulatory progress and how opakalim fits into a competitive epilepsy landscape shaped by mechanism diversity and payer expectations.